Mobidiag’s Novodiag Stool Parasites test secures CE-IVD Mark

10 October 2019 (Last Updated October 10th, 2019 11:50)

Finnish molecular diagnostics firm Mobidiag has received CE-IVD marking for its Novodiag Stool Parasites test designed to identify intestinal parasites.

Finnish molecular diagnostics firm Mobidiag has received CE-IVD marking for its Novodiag Stool Parasites test designed to identify intestinal parasites.

The syndromic, fully automated, qualitative test uses real-time polymerase chain reaction (PCR) and microarray technologies to detect the nucleic acid markers of the most common protozoan, helminths and microsporidia in stool samples.

Novodiag Stool Parasites test runs on-demand on the automated Novodiag system and can deliver complete results in 90 minutes, requiring less than five minutes of hands-on time by an operator.

The test could also help address the increasing incidence of parasitic diseases in developed countries, where a shortage of microscopy trained staff exists.

Mobidiag CEO Tuomas Tenkanen said: “Parasitic diseases contribute significantly to the burden of infectious diseases worldwide and current diagnostic methods such as microscopy are labour-intensive and require a high level of skill.

“Our Novodiag Stool Parasites test is the only fully automated, rapid, cost-effective and easy to use diagnostic solution that can identify a comprehensive range of parasitic targets, for use in laboratories and hospitals.”

Novodiag Stool Parasites is the fourth test based on the company’s Novodiag platform, launched after the C. difficile, Bacterial GE+ and CarbaR+ tests.

Novodiag is a fully automated molecular testing platform designed for diagnostics of infectious diseases and antibiotic resistance.

The platform provides a direct analysis of patient samples for comprehensive screening of several or one pathogens.

Last year, Mobidiag entered a deal with Chinese clinical diagnostics company Autobio Diagnostics to form a joint venture (JV) for commercialising the Novodiag platform in China.

Under the agreement, Mobidiag will provide the JV with an exclusive licence for human infectious disease assays in China.